Skip to main content
Sudhir Manda, MD, Oncology, Tucson, AZ

SudhirMandaMD

Oncology Tucson, AZ

Physician

Dr. Manda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Manda's full profile

Already have an account?

  • Office

    603 N Wilmot Rd
    Ste 151
    Tucson, AZ 85711
    Phone+1 520-886-0206
    Fax+1 520-886-0829

Education & Training

  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
  • The MetroHealth System/Case Western Reserve University
    The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2005 - 2008
  • Gandhi Medical College
    Gandhi Medical CollegeClass of 2002

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2015 - 2025
  • NH State Medical License
    NH State Medical License Active through 2015
  • OH State Medical License
    OH State Medical License 2005 - 2014

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
    Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
    Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
    Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019